Serum lactate dehydrogenase level in pre-eclampsia and its correlation with maternal and fetal outcome


  • Niyanta P. Vyas Department of Obstetrics and Gynecology, Chirayu Hopsital, Dahod, Gujarat, India
  • Nandini Gopalakrishna Department of Obstetrics and Gynecology, M. S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India
  • Jessica Fernandes Department of Obstetrics and Gynecology, M. S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India



Abruptio placenta, Disseminated intravascular coagulation, Foetal growth restriction, HELLP syndrome, Lactate dehydrogenase, Pre-eclampsia


Background: Hypertensive disorders are the most common medical disorders during pregnancy. It increases maternal and perinatal morbidity and mortality. The incidence is 7 to 10%. Identifying high risk patients and close monitoring can reduce the complications. Lactate dehydrogenase is a useful biochemical marker and can be used to evaluate maternal complications like Disseminated intravascular coagulation (DIC), HELLP syndrome (Haemolysis, elevated liver enzymes and lowered platelets), pulmonary edema, renal failure and fetal complications like Fetal growth restriction (FGR) APGAR score ≤7 at 5 min and Neonatal intensive care unit (NICU) admissions. The objective of this study was to estimate serum Lactate dehydrogenase levels (LDH) in pre-eclampsia patients and study the correlation between increased LDH levels and maternal and fetal outcome.

Methods: It was a prospective study from October 2015 to May 2017 at M. S. Ramaiah medical college and hospitals, Bangalore.

Results: The incidence of maternal and foetal complications was increased with higher serum LDH levels. With serum LDH >than 600 IU/l the incidence of HELLP syndrome, DIC, pulmonary edema was statistically significant. It also correlated with increased creatinine levels and decreased platelets with p value<0.001. The foetal complications including FGR NICU admission and Apgar score <7 at 5 min was statistically significant. The liver enzymes and serum creatinine correlated with increased LDH levels.

Conclusions: Maternal and foetal complications are increased with raised LDH levels, and it can be used as a biochemical marker to achieve a better outcome.


Marlene MC. William’s Obstetrics. 24th ed. Doctorlib; 2014: 728-770.

Vinitha PM, Chellatamizh M, Padmanaban S. Role of serum LDH in pre-eclampsia as a prognostic factor- a cross sectional case control study in tertiary care hospital. Int J Repord Contracept Obstet Gynaecol. 2017;6:595-8.

Hak J, Nisa NU, Gupta S. LDH levels in pregnancy and its association with severity of the disease and feto-maternal outcome in pre-eclampsia and eclampsia. JK Sci. 2015;17(3):110-3.

Gupte S, Wagh G. Preeclampsia-eclampsia. J Obstet Gynaecol India. 2014;64(1):4-13.

Petla LT, Chikkala R, Ratnakar KS, Kodati V, Sritharan V. Biomarkers for the management of pre-eclampsia in pregnant women. Indian J Med Res. 2013;138(1):60-7.

He S, Bremme K, Kallner A, Blombäck M. Increased concentrations of lactate dehydrogenase in pregnancy with preeclampsia: a predictor for the birth of small-for-gestational-age infants. Gynecol Obstet Invest. 1995;39(4):234-8.

Qublan HS, Ammarin V, Bataineh O, Shraideh Z, Tahat Y, Awamleh I, Khreisat B, et al. Lactic dehydrogenase as a biochemical marker of adverse pregnancy outcome in severe pre-eclampsia. Med Sci Monit. 2005;11(8):393-7.

Sharma U, Hariharan C. Maternal and outcome in PIH patients in relation with serum LDH levels. IOSR J Dent Med Sci. 2017;16(1):1-4.

Bera S, Gupta S, Saha S, Kunti S, Biswas S, Ghosh D. Study of Liver Enzymes Especially Lactate Dehydrogenase to Predict Foetal Outcome in Pregnancy Induced Hypertension. Scholar’s J Applied Med Sci. 2014;2(5):1569-72.

Walker JJ. Pre-eclampsia. Lancet. 2000;356(9237):1260-5.

Dave A, Maru L, Jain A. LDH (Lactate Dehydrogenase): A Biochemical Marker for the Prediction of Adverse Outcomes in Pre-eclampsia and Eclampsia. J Obstet Gynaecol India. 2016;66(1):23-9.

Jaiswar SP, Gupta A, Sachan R, Natu SN, Shaili M. Lactic dehydrogenase: a biochemical marker for preeclampsia-eclampsia. J Obstet Gynaecol India. 2011;61(6):645-8.

Doddamani UG, Doddamani GB. Perinatal Outcome in Pre-Eclampsia: A Prospective Study. Sch J App Med Sci. 2014;2(1):291-3.

Aziz R, Mahboob T. Relation between preeclampsia and cardiac enzymes. Atheroscl J. 2008;4(1):29-32.

Umastayasri Y, Vani I, Shamita P. Role of LDH (Lactate Dehydrogenase) in preeclampsia-eclampsia as a prognostic marker: An observational study. Int Arch Integrat Med. 2015;2(9):88-93.

Hazari NR, Hatolkar VS, Munde SM. Study of Serum Hepatic Enzymes in Preeclampsia. Int J Current Med App Sci. 2014;2(1):1-8.

Agrawal S, Walia GK. Prevalence and risk factors for Preeclampsia in Indian women: a national cross-sectional study. South Asia network for chronic disease. Public Health Found India. 2014;1-23.

Hall DR, Odendaal HJ, Kirsten GF, Smith J, Grové D. Expectant management of early onset, severe pre-eclampsia: perinatal outcome. BJOG. 2000;107(10):1258-64.

Seed PT, Chappell LC, Black MA, Poppe KK, Hwang YC, Kasabov N, et al. Prediction of preeclampsia and delivery of small for gestational age babies based on a combination of clinical risk factors in high-risk women. Hypertens Pregnancy. 2011;30(1):58-73.

Townsend R, Brien P, Khalil A. Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control. 2016;9:79-94.






Original Research Articles